Alnylam Pharmaceuticals
ALNY
#622
Rank
ยฃ26.08 B
Marketcap
ยฃ202.26
Share price
-1.16%
Change (1 day)
36.34%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -ยฃ0.15 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ2.09 Billion. In 2023 the company made an earning of -ยฃ0.26 Billion, an increase over its 2022 earnings that were of -ยฃ0.8 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -ยฃ0.15 Billion-43.87%
2023 -ยฃ0.26 Billion-67.84%
2022 -ยฃ0.8 Billion36.93%
2021 -ยฃ0.59 Billion-8.04%
2020 -ยฃ0.64 Billion-15.66%
2019 -ยฃ0.76 Billion12.23%
2018 -ยฃ0.67 Billion62.91%
2017 -ยฃ0.42 Billion17.78%
2016 -ยฃ0.35 Billion43.44%
2015 -ยฃ0.25 Billion60.69%
2014 -ยฃ0.16 Billion98.2%
2013 -ยฃ76.34 Million
2011 -ยฃ45.03 Million27.48%
2010 -ยฃ35.32 Million-10.92%
2009 -ยฃ39.65 Million95.77%
2008 -ยฃ20.26 Million
2006 -ยฃ32.45 Million-9.13%
2005 -ยฃ35.71 Million34.74%
2004 -ยฃ26.5 Million36.79%
2003 -ยฃ19.38 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ0.48 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ4.08 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.10 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ96.79 Million-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ33.98 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.45 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ6.08 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ0.34 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel